Drug profile · INN
tabelecleucel
EBVALLO
tabelecleucel (EBVALLO) is a the t-cell receptor recognises an ebv peptide in complex with a specific hla molecule on the surface of target cells to exert cytotoxic activity.
Drug details — tabelecleucel
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 4
- Data quality
- 0.83
Quick answer
tabelecleucel (EBVALLO) is a the t-cell receptor recognises an ebv peptide in complex with a specific hla molecule on the surface of target cells to exert cytotoxic activity.
Key facts
Mechanism of action
The T-cell receptor recognises an EBV peptide in complex with a specific HLA molecule on the surface of target cells to exert cytotoxic activity
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Recent coverage
Atara Biotherapeutics Receives FDA Complete Response Letter for EBVALLO Cancer Treatment, Faces Securities Class Action
Atara Biotherapeutics' EBVALLO cancer therapy receives FDA Complete Response Letter, delaying approval as company faces securities class action lawsuit deadline May 22, 2026.
FDA Issues Complete Response Letter for Atara Biotherapeutics' EBVALLO Cancer Treatment, Triggering Securities Lawsuit
Atara Biotherapeutics receives FDA Complete Response Letter for EBVALLO (tabelecleucel) cancer treatment, leading to securities class action lawsuit deadline.
Pipeline programs
Frequently asked questions
What is tabelecleucel?
tabelecleucel (EBVALLO) is a the t-cell receptor recognises an ebv peptide in complex with a specific hla molecule on the surface of target cells to exert cytotoxic activity.
What is the brand name for tabelecleucel?
EBVALLO is a marketed brand name for tabelecleucel. Check FDA Drugs@FDA for the current US label holder and prescribing information.